| Literature DB >> 25941501 |
Andrea Clarici1, Sandra Pellizzoni2, Secondo Guaschino2, Salvatore Alberico2, Stefano Bembich2, Rosella Giuliani2, Antonia Short3, Giuseppina Guarino1, Jaak Panksepp4.
Abstract
Oxytocin is a neuropeptide that is active in the central nervous system and is generally considered to be involved in prosocial behaviors and feelings. In light of its documented positive effect on maternal behavior, we designed a study to ascertain whether oxytocin exerts any therapeutic effects on depressive symptoms in women affected by maternal postnatal depression. A group of 16 mothers were recruited in a randomized double-blind study: the women agreed to take part in a brief course of psychoanalytic psychotherapy (12 sessions, once a week) while also being administered, during the 12-weeks period, a daily dose of intranasal oxytocin (or a placebo). The pre-treatment evaluation also included a personality assessment of the major primary-process emotional command systems described by Panksepp () and a semi-quantitative assessment by the therapist of the mother's depressive symptoms and of her personality. No significant effect on depressive symptomatology was found following the administration of oxytocin (as compared to a placebo) during the period of psychotherapy. Nevertheless, a personality trait evaluation of the mothers, conducted in our overall sample group, showed a decrease in the narcissistic trait only within the group who took oxytocin. The depressive (dysphoric) trait was in fact significantly affected by psychotherapy (this effect was only present in the placebo group so it may reflect a positive placebo effect enhancing the favorable influence of psychotherapy on depressive symptoms) but not in the presence of oxytocin. Therefore, the neuropeptide would appear to play some role in the modulation of cerebral functions involved in the self-centered (narcissistic) dimension of the suffering that can occur with postnatal depression. Based on these results, there was support for our hypothesis that what is generally defined as postnatal depression may include disturbances of narcissistic affective balance, and oxytocin supplementation can counteract that type of affective disturbance. The resulting improvements in well-being, reflected in better self-centering in post-partuent mothers, may in turn facilitate better interpersonal acceptance of (and interactions with) the child and thereby, improved recognition of the child's needs.Entities:
Keywords: double-blind method; emotion regulation; oxytocin; postnatal depression; psychoanalytic therapy
Year: 2015 PMID: 25941501 PMCID: PMC4403302 DOI: 10.3389/fpsyg.2015.00426
Source DB: PubMed Journal: Front Psychol ISSN: 1664-1078
List of Beck’s (2001) criteria for postpartum depression.
| Significant predictors for postpartum depression ( |
|---|
| Prenatal depression |
| Low self-esteem |
| Child-care stress |
| Prenatal anxiety |
| Life stress |
| Low social support |
| Poor marital relationship |
| Difficult infant temperament |
| Maternity blues |
| Single marital status |
| Unplanned/unwanted pregnancy |
| Low socioeconomic status |
| History of previous depression |
Characteristics of the mothers included in the study.
| Age | Nationality | Parity | Breastfeed | |
|---|---|---|---|---|
| 1 | 41 | Ita | 2 | yes |
| 2 | 39 | Ita | 1 | yes |
| 3 | 34 | Ita | 2 | yes |
| 4 | 38 | Ita | 1 | yes |
| 5 | 33 | Ita | 1 | yes |
| 1 | 38 | Ita | 1 | 1 months |
| 2 | 33 | Outside EU | 1 | Yes |
| 3 | 35 | Ita | 1 | Yes |
| 4 | 41 | EU | 1 | 4 months |
| 5 | 42 | Ita | 1 | Yes |
| 6 | 38 | Ita | 2 | No |
| 7 | 38 | Outside EU | 2 | Yes |
| 8 | 39 | Ita | 1 | Yes |
| 9 | 38 | Ita | 1 | Yes |
| 10 | 29 | Ita | 1 | Yes |
| 11 | 33 | Ita | 2 | Yes |
Experimental design and sequence of the assessments.
| # | Encounters | General administration | Assessment tools |
|---|---|---|---|
| 1st | Referral | Randomization (assignment to the placebo or to the oxytocin group | |
| 2nd | Pre-treatment assessment meeting | No substance administration | EPDS, HDRS, ANPS scales |
| 3rd | First psychotherapic encounter | Beginning of the daily administration of substance (either Oxytocin or Placebo) | SWAP scale by the therapist after the first session |
| 4th– 13th | Weekly sessions of psychotherapy (globally 12 sessions) | Continuation of daily administration of substance (either oxytocin or placebo) | Weekly follow-up supervision sessions by the team of psychotherapists |
| 14th | On the 12th Psychotherapic encounter | Continuation of daily administration of substance (either oxytocin or placebo) | SWAP scale by the therapist after the last session |
| 15th | Post-treatment assessment meeting | Discontinuation of daily administration of substance | EPDS, HDRS, ANPS scales |
Average scores from all independent variables considered in this study in the Oxytocin and Placebo groups (results from comparisons between groups were not significant in U Mann–Whitney test. The SWAP scores resulted significant using the Wilcoxon Signed-Rank test.).
| EPDS | HDRS | SWAP | ||||||
|---|---|---|---|---|---|---|---|---|
| Narcissistic | Dysphoric | |||||||
| Pre | Post | Pre | Post | Pre | Post | Pre | Post | |
| Oxytocin group | 15,2 | 11,8 | 12,8a | 11,2b | 45,91 | 42,31 | 50,0 | 47,6 |
| Placebo group | 13,23 | 9,3 | 15,4a | 9,4b | 40,1 | 41,7 | 52,92 | 48,32 |
| Significance | Δ (a-b): | Δ1: | Δ2: | |||||